NAVB - Navidea Biopharm GAAP EPS of -$0.10 revenue of $0.06M August, 15 2022 08:45 AM Navidea Biopharmaceuticals Inc. Navidea Biopharm press release ( NYSE: NAVB ): Q2 GAAP EPS of -$0.10. Revenue of $0.06M (-76.9% Y/Y). Navidea ended the second quarter of 2022 with $328,000 million in cash and cash equivalents. Shares +1.92% PM For further details see: Navidea Biopharm GAAP EPS of -$0.10, revenue of $0.06M